Vikram K. Chand

3.5k total citations · 2 hit papers
68 papers, 1.8k citations indexed

About

Vikram K. Chand is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Accounting. According to data from OpenAlex, Vikram K. Chand has authored 68 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 20 papers in Accounting. Recurrent topics in Vikram K. Chand's work include Lung Cancer Treatments and Mutations (28 papers), Corporate Taxation and Avoidance (18 papers) and Lung Cancer Research Studies (17 papers). Vikram K. Chand is often cited by papers focused on Lung Cancer Treatments and Mutations (28 papers), Corporate Taxation and Avoidance (18 papers) and Lung Cancer Research Studies (17 papers). Vikram K. Chand collaborates with scholars based in United States, Germany and France. Vikram K. Chand's co-authors include Bushi Wang, James L. Gulley, Anja von Heydebreck, Yelena Y. Janjigian, Leora Horn, Egbert F. Smit, Harry J.M. Groen, D. Ross Camidge, Vincent A. Miller and Scott Gettinger and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Vikram K. Chand

56 papers receiving 1.7k citations

Hit Papers

Afatinib versus erlotinib as second-line treatment of pat... 2015 2026 2018 2022 2015 2019 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
    2015 324 citations Jean‐Charles Soria, Enriqueta Felip et al. profile →
  2. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
    2019 319 citations Matthew H. Taylor, Karen Kelly et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vikram K. Chand United States 16 1.2k 984 387 304 226 68 1.8k
Roberto Sabbatini Italy 26 459 0.4× 642 0.7× 523 1.4× 385 1.3× 99 0.4× 122 2.6k
Axel Walther United Kingdom 12 752 0.6× 196 0.2× 658 1.7× 538 1.8× 109 0.5× 40 1.8k
Bob T. Li United States 31 3.3k 2.8× 2.2k 2.2× 1.1k 2.8× 773 2.5× 501 2.2× 147 4.6k
Ben Tran Australia 26 1.6k 1.3× 980 1.0× 828 2.1× 530 1.7× 248 1.1× 171 2.9k
Tien Hoang United States 22 1.8k 1.5× 1.4k 1.5× 414 1.1× 227 0.7× 276 1.2× 70 2.4k
J. Andrew Livingston United States 19 475 0.4× 513 0.5× 416 1.1× 247 0.8× 193 0.9× 92 1.4k
А. Н. Махсон Russia 15 1.2k 1.0× 563 0.6× 310 0.8× 397 1.3× 93 0.4× 23 1.7k
Sreenivasa Nattam United States 20 1.9k 1.6× 1.0k 1.1× 760 2.0× 378 1.2× 182 0.8× 42 2.6k
Vera Gorbounova Russia 13 2.2k 1.9× 1.8k 1.9× 617 1.6× 354 1.2× 151 0.7× 23 3.2k
Karin Bowen United States 15 1.3k 1.1× 942 1.0× 809 2.1× 359 1.2× 502 2.2× 30 2.8k

Countries citing papers authored by Vikram K. Chand

Since Specialization
Citations

This map shows the geographic impact of Vikram K. Chand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vikram K. Chand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vikram K. Chand more than expected).

Fields of papers citing papers by Vikram K. Chand

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vikram K. Chand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vikram K. Chand. The network helps show where Vikram K. Chand may publish in the future.

Co-authorship network of co-authors of Vikram K. Chand

This figure shows the co-authorship network connecting the top 25 collaborators of Vikram K. Chand. A scholar is included among the top collaborators of Vikram K. Chand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vikram K. Chand. Vikram K. Chand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Melillo, Giovanni, Vikram K. Chand, Alejandro Yovine, Ashok Gupta, & Cristian Massacesi. (2021). Curative-Intent Treatment with Durvalumab in Early-Stage Cancers. Advances in Therapy. 38(6). 2759–2778. 13 indexed citations
3.
Si, Han, Michael Kuziora, Katie Quinn, et al.. (2020). A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study. Clinical Cancer Research. 27(6). 1631–1640. 86 indexed citations
4.
Chand, Vikram K., et al.. (2020). Pillar II of the Digital Debate: Our View on the Approach Towards Blending and Substance Carve Outs to Determine Effective Tax Rates. SERVAL (Université de Lausanne). 3 indexed citations
5.
Chand, Vikram K., et al.. (2020). Profit Allocation within MNEs in Light of the Ongoing Digital Debate on Pillar I – A “2020 Compromise”?. World Tax Journal. 12(3). 565–630.
6.
Chand, Vikram K., et al.. (2019). The Relevant Economic Activity Test and its Impact on the International Corporate Tax Policy Framework. SERVAL (Université de Lausanne). 394–424. 1 indexed citations
7.
Taı̈eb, Julien, Markus Moehler, Narikazu Boku, et al.. (2018). Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. Cancer Treatment Reviews. 66. 104–113. 72 indexed citations
8.
Tourneau, Christophe Le, Christopher Hoimes, Corrine Zarwan, et al.. (2018). Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. Journal for ImmunoTherapy of Cancer. 6(1). 111–111. 122 indexed citations
9.
Chand, Vikram K.. (2017). Should States Opt for the Saving Clause in the Multilateral Instrument. IRIS. 86. 689–694. 1 indexed citations
10.
Jérusalem, Guy, Franklin Chen, David R. Spigel, et al.. (2017). OA03.03 JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti-PD-L1) as First-Line Treatment in Patients with Advanced NSCLC. Journal of Thoracic Oncology. 12(1). S252–S252. 19 indexed citations
11.
Reck, Martin, James Chih‐Hsin Yang, Pieter E. Postmus, et al.. (2017). JAVELIN Lung 100: updated design of a phase 3 trial of avelumab vs platinum doublet chemotherapy as first-line (1L) treatment for metastatic or recurrent PD-L1+ non-small-cell lung cancer (NSCLC). Annals of Oncology. 28. v492–v492. 5 indexed citations
12.
Chin, Kevin M., Vikram K. Chand, & Dimitry S.A. Nuyten. (2017). Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy. Annals of Oncology. 28(7). 1658–1666. 27 indexed citations
13.
14.
15.
16.
Grève, Jacques De, Teresa Morán, Marie-Pascale Graas, et al.. (2015). Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Lung Cancer. 88(1). 63–69. 69 indexed citations
17.
Janjigian, Yelena Y., Egbert F. Smit, Harry J.M. Groen, et al.. (2014). Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR -Mutant Lung Cancer with and without T790M Mutations. Cancer Discovery. 4(9). 1036–1045. 295 indexed citations
18.
Chu, Quincy S., Randeep Sangha, Sébastien J. Hotte, et al.. (2014). A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. Investigational New Drugs. 32(6). 1226–1235. 7 indexed citations
19.
20.
Chand, Vikram K., Christopher J. Sweeney, & William A. Agger. (1997). Mental Neuropathy in Patients with AIDS-Associated Malignant Lymphoma. Clinical Infectious Diseases. 24(3). 521–522. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roberto Sabbatini Breakdown of academic impact, for papers by Axel Walther Breakdown of academic impact, for papers by Bob T. Li Breakdown of academic impact, for papers by Ben Tran Breakdown of academic impact, for papers by Tien Hoang Breakdown of academic impact, for papers by J. Andrew Livingston Breakdown of academic impact, for papers by А. Н. Махсон Breakdown of academic impact, for papers by Sreenivasa Nattam Breakdown of academic impact, for papers by Vera Gorbounova Breakdown of academic impact, for papers by Karin Bowen
Rankless by CCL
2026